Abstract: The present disclosure provides isolated polynucleotides encoding a mature Mycobacterium tuberculosis protein selected from Ag85A, Ag85B, and Ag85C, where the protein does not include a signal for glycosylation, such as a N-glycosylation consensus sequon. Also disclosed are M. tuberculosis proteins selected from Ag85A, Ag85B, and Ag85C that do not include a signal for glycosylation, such as a N-glycosylation consensus sequon, and/or are not glycosylated, and methods for using the polynucleotides and proteins.
Type:
Application
Filed:
December 8, 2020
Publication date:
January 12, 2023
Applicant:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Abstract: The invention generally provides methods of treating or preventing infection and/or disease associated with different fungal pathogens in a subject in need, using an isolated antiserum generated against an immunogenic peptide of one fungal pathogen that contains antibodies that cross-protect the subject from infection and/or disease associated with one or more different fungal pathogens. The antiserum may be generated against a Kexin peptide derived from one of a Pneumocystis, Aspergillus, Candida, or Cryptococcus fungal pathogen. The resulting cross-protective, isolated antiserum may be used as a therapeutic for treating or protecting a subject who receives the antiserum against infection and/or disease associated with multiple fungal pathogens, in addition to the pathogen against which the antiserum is generated.
Type:
Grant
Filed:
September 26, 2018
Date of Patent:
January 10, 2023
Assignee:
University of Georgia Research Foundation, Inc.
Inventors:
Karen A. Norris, Whitney Rabacal, Emily Rayens
Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
January 3, 2023
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Abstract: The invention generally provides methods of treating or preventing aspergillosis disease and/or its symptoms associated with infection by the Aspergillus pathogenic fungus. The methods involve administering an Aspergillus Kexin peptide, or a composition comprising an Aspergillus peptide, to a mammalian subject in need thereof, such as a subject afflicted with aspergillus, or a subject susceptible to or at risk of infection by Aspergillus and ensuing aspergillosis disease. In some aspects, the Aspergillus Kexin peptide is an A. fumigatus Kexin peptide. In some aspects, the mammalian subject is a human patient. In some aspects, the patient is immunosuppressed or immunocompromised. The Aspergillus Kexin peptide as immunogen or vaccine generates a potent and robust immune response, e.g., antibody response, in the immunized subject. The methods afford therapeutic and protective treatment against aspergillosis and its symptoms, as well as a reduction in the severity of aspergillosis in the treated subjects.
Type:
Application
Filed:
November 12, 2020
Publication date:
December 22, 2022
Applicant:
University of Georgia Research Foundation, Inc.
Inventors:
Emily Anne RAYENS, Whitney RABACAL, Karen NORRIS
Abstract: The present disclosure relates to nanoparticle compositions for use as vaccines against Clostridium perfringens in poultry which causes necrotic enteritis in poultry. Such compositions include one or more Clostridium perfringens extracellular proteins entrapped in a polyanhydride or chitosan nanoparticle. The one or more Clostridium perfringens extracellular proteins may include one or more Clostridium perfringens toxins, such as, for example, alpha toxin (CPA), beta toxin (CPB), epsilon toxin (ETX), iota toxin (ITX), perfringolysin O (PFO), enterotoxin (CPE), beta2 toxin (CPB2), or NetB toxin. In some aspects, the composition further includes a Salmonella enteritidis flagellar protein. The present invention also includes methods for the oral delivery of one or more Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
December 13, 2022
Assignees:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC, THE OHIO STATE UNIVERSITY
Inventors:
Ramesh Kumar Selvaraj, Gabriel Akerele, Sankar Renu, Renukaradhya J. Gourapura
Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
December 13, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Inventors:
Donald A. Harn, Rafaella Queiroz, Lisa Shollenberger, Emily-Joy Farah Samli
Abstract: Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
February 14, 2017
Date of Patent:
December 6, 2022
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Inventors:
Somanath Rammohan Shenoy, Brian S. Cummings, Wided Najahi-Missaoui
Abstract: The present disclosure provides methods, electrodes, and systems for electrochemical oxidation of polyfluoroalkyl and perfluroalkyl (PFAS) contaminants using Magnéli phase titanium suboxide ceramic electrodes/membranes. Magneli phase titanium suboxide ceramic electrodes/membranes can be porous and can be included in reactive electrochemical membrane filtration systems for filtration, concentration, and oxidation of PFASs and other contaminants.
Type:
Grant
Filed:
August 18, 2017
Date of Patent:
November 29, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: The present disclosure relates to a monitoring system configured to monitor the activities of individuals without having to keep the surrounding area under the surveillance of a camera thereby maintaining the privacy of the individual. In particular, the monitoring system includes a network of sensitive sensor units that are installed onto indoor flooring to record human footstep induced vibrations. The data collected from the sensors can then be processed to identify individual occupants, determine the number of occupants, estimate the location of footsteps, and track the trajectory of each occupant. The extracted trajectory information can be used to assess an occupant's personal activity and social interaction, which can then be used to analyze the individual's physical and psychological health.
Type:
Grant
Filed:
February 6, 2020
Date of Patent:
November 8, 2022
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC
Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
Type:
Application
Filed:
June 13, 2022
Publication date:
November 3, 2022
Applicant:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Inventors:
Donald A. Harn, Rafaella Queiroz, Lisa Shollenberger, Emily-Joy Farrah Samli
Abstract: A new and distinct cultivar of Hibiscus plant named ‘RutHib5’ is characterized by a combination of compact rounded form with medium vigor, attractive white flowers with a red eye, bicolor, reddish green foliage with pubescence, and good resistance to Alternaria alternata, Cercospora, and Hibiscus sawfly.
Type:
Grant
Filed:
July 16, 2021
Date of Patent:
November 1, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Distylium plant named ‘DISmd-09-15’, characterized by its compact, upright, and evergreen plant habit, and its ovate-lanceolate shaped leaves, that are dark green once mature and bronze-red in color when young. The inventor believes it could be used as a screening hedge in the South.
Type:
Grant
Filed:
April 22, 2022
Date of Patent:
November 22, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Vaccinium plant named ‘TH-896’, characterized by a combination of early to mid-season ripening and flowering; large berries with good flavor, firmness, and scar; and a medium chilling requirement of about 300-400 hours, or more, below about 45° F.
Type:
Grant
Filed:
January 13, 2022
Date of Patent:
November 29, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Vaccinium plant named ‘TH-1241’, characterized by a combination of early season ripening and short fruit development period; large berries with good color and flavor; highly vigorous growth; and a medium chilling requirement of about 350-450 hours, or more, below about 45° F.
Type:
Grant
Filed:
January 13, 2022
Date of Patent:
November 29, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Vaccinium plant named ‘TH-1987’, characterized by a combination of early season ripening and flowering, large berries with good flavor, firmness, and scar; and a low chill requirement about 150 hours, or less, below about 45° F.
Type:
Grant
Filed:
May 17, 2022
Date of Patent:
November 29, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Distylium plant named ‘DISmd-24-18’, characterized by its compact, tight, and evergreen plant habit, and its ovate-lanceolate shaped leaves, that are dark green once mature and bronze-pink in color when young. The inventor believes it could be used as a foundation plant in the South.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
December 13, 2022
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Vaccinium plant named ‘TH-1093’, characterized by a combination of early to mid-season ripening and flowering; large berries with good flavor, firmness, and scar; and a medium chilling requirement of about 350 to 450 hours, or more, below about 45° F.
Type:
Grant
Filed:
July 12, 2022
Date of Patent:
January 17, 2023
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A pecan tree distinguished by the following unique combination of characteristics: large nut size, bright kernel color, good shelling ability, moderately early harvest date, and good resistance to the scab fungus (Venturia effuse) in sprayed orchards.
Type:
Grant
Filed:
March 4, 2022
Date of Patent:
January 24, 2023
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: A new and distinct cultivar of Vaccinium plant named ‘TO-1719’, characterized by a combination of early to mid-season ripening and flowering, large, firm berries with good color, and mild sweet and acid flavor; and a chill requirement of about 350 to 450 hours, or more, below about 45° F.
Type:
Grant
Filed:
July 12, 2022
Date of Patent:
January 24, 2023
Assignee:
University of Georgia Research Foundation, Inc.